English Swedish
Published: 2022-03-31 15:05:00 CEST
C-Rad AB
Inside information

C-RAD receives order on its SGRT solution to US Proton Therapy centre

C-RAD announced today an agreement to supply its cutting-edge SGRT solution to a newly built proton therapy center in Texas, US. The agreement includes multiple systems and a multiyear service agreement.

The center is equipped with a Hitachi proton therapy system with four treatment rooms. Two treatment rooms will be equipped with the C-RAD technology in the initial phase with an option to further expand into the other rooms. The new center is expected to assume clinical treatments in early 2023.

The C-RAD SGRT (Surface Image Guided Radiation Therapy) solution with the Sentinel 4DCT™ and Catalyst HD™ technology was chosen to optimize patient safety before and during treatment, efficiency and precision to support advanced treatment techniques such as DIBH (Deep Inspiration Breath Hold) and SRT (Stereotactic Radiation Therapy).

The Catalyst system will be delivered with the complete software suite including modules for Respiratory Gating, Patient Setup & Positioning as well as Motion Monitoring. The C-RAD SGRT system (Surface Guided Radiation Therapy) provides the customer with a tool for accurate patient setup prior to the treatment and continuous monitoring of the patient during a treatment fraction. The technology provides accuracy and safety for the patient to support high precision treatment techniques as well as efficiency in a complex treatment workflow.

“We are truly excited about the collaboration with this proton therapy center” says Tim Thurn, CEO and President of C-RAD AB, “Proton therapy is considered to be the spearhead of precision radiation therapy. Accurate tumor positioning and monitoring during treatment is a key factor for a successful treatment.”

The total order has a value of approx. 9 MSEK for C-RAD. Delivery and installation are expected to commence within the next months.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

This information is information that C-Rad is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-03-31 15:05 CEST.


C-RAD receives order on its SGRT solution to US Proton Therapy centre.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page